<< Baucus target of ad favoring a public option | HHS to discuss the release of new resources to support health information technology >>
Read in | English | Español | Français | Deutsch | Italiano | 日本語 | 한국어 | 简体中文 | Nederlands

Research And Markets' new report on global diabetes market

Published on September 29, 2009 at 5:15 AM · No Comments

Research and Markets(http://www.researchandmarkets.com/research/c15b35/global_diabetes_ma) has announced the addition of Frost & Sullivan's new report "Global Diabetes Market" to their offering.

This Frost & Sullivan research service titled Global Diabetes Market provides insight into key industry challenges, market drivers and trends. Defining trends are examined along with revenue forecasts. A SWOT analysis is provided of the diabetes markets in the United States, Europe, Japan and rest of the world. In this research, Frost & Sullivan's expert analysts thoroughly examine the following diabetes markets: the US, Europe, Japan and the Rest-of-World. Insulin and insulin analogues and non-insulin anti-diabetic drugs markets are also studied in the research.

Market Overview

Emergence of Novel Drug Classes to Boost Market Growth

Increasing knowledge related to the pathology of diabetes will support the introduction of improved drugs to treat the disease. As healthcare moves towards the ideal of preventive medicine, there are a few companies conducting research on diabetes vaccines. If they succeed, the entire market landscape is bound to undergo instant change.

"Improved therapies and innovative drug delivery techniques are anticipated to revolutionise the global diabetes market by 2015," notes the analyst of this research. "As healthcare moves towards preventive medicine, the search for a cure for diabetes looks promising." The emergence of newer classes of drugs to treat diabetes and their co-morbidities is changing the diabetes market landscape. Long-acting GLP-1 analogs are likely to gain significance and almost match the importance of insulin in the near future. This trend is likely to be beneficial for Type-2 diabetics who have not responded to other oral anti-diabetic agents.

Asian Markets Offer Considerable Growth Potential

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading